The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
Open accessAbstract
Primary focal segmental glomerulosclerosis (FSGS) is a disease with poor prognosis and high unmet therapeutic need. Here, we evaluated the safety and pharmacokinetics of single-dose infusions of fresolimumab, a human monoclonal antibody that inactivates all forms of transforming growth factor-β (TGF-β), in a phase I open-label, dose-ranging study. Patients with biopsy-confirmed, treatment-resistant, primary FSGS with a minimum estimated glomerular filtration rate (eGFR) of 25 ml/min per 1.73 m(2), and a urine protein to creatinine ratio over 1.8 mg/mg were eligible. All 16 patients completed the study in which each received one of four single-dose levels of fresolimumab (up to 4 mg/kg) and was followed for 112 days. Fresolimumab was well tolerated with pustular rash the only adverse event in two patients. One patient was diagnosed with a histologically confirmed primitive neuroectodermal tumor 2 years after fresolimumab treatment. Consistent with treatment-resistant FSGS, there was a slight decline in eGFR (median decline baseline to final of 5.85 ml/min per 1.73 m(2)). Proteinuria fluctuated during the study with the median decline from baseline to final in urine protein to creatinine ratio of 1.2 mg/mg with all three Black patients having a mean decline of 3.6 mg/mg. The half-life of fresolimumab was ∼14 days, and the mean dose-normalized Cmax and area under the curve were independent of dose. Thus, single-dose fresolimumab was well tolerated in patients with primary resistant FSGS. Additional evaluation in a larger dose-ranging study is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Self-citationPathologic classification of focal segmental glomerulosclerosis: a working proposal
D'Agati, V. D., Fogo, A. B., Bruijn, J. A., & Jennette, J. C. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.10.024 · Cited by 776
Apoptosis in podocytes induced by TGF-β and Smad7
Schiffer, M., Bitzer, M., Roberts, I. S. D., Kopp, J. B., ten Dijke, P., Mundel, P., & Böttinger, E. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12367 · Cited by 598
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
The Notch pathway in podocytes plays a role in the development of glomerular disease
Niranjan, T., Bielesz, B., Gruenwald, A., Ponda, M. P., Kopp, J. B., Thomas, D. B., & Susztak, K. (2008) · Nature Medicine · doi:10.1038/nm1731 · Cited by 427
Cattran, D. C., Appel, G. B., Hebert, L. A., Hunsicker, L. G., Pohl, M. A., Hoy, W. E., Maxwell, D. R., & Kunis, C. L. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00778.x · Cited by 326
A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome
Ponticelli, C., Rizzoni, G., Edefonti, A., Altieri, P., Rivolta, E., Rinaldi, S., Ghio, L., Lusvarghi, E., Gusmano, R., Locatelli, F., et al. (1993) · Kidney International · doi:10.1038/ki.1993.194 · Cited by 288
Focal and Segmental Glomerulosclerosis: Definition and Relevance of a Partial Remission
Troyanov, S., Wall, C. A., Miller, J. A., Scholey, J. W., & Cattran, D. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070593 · Cited by 282
Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials
Gansevoort, R. T., Sluiter, W. J., Hemmelder, M. H., de Zeeuw, D., & de Jong, P. E. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.11.1963 · Cited by 259
Idiopathic membranous nephropathy: Definition and relevance of a partial remission
Troyanov, S., Wall, C. A., Scholey, J. W., Miller, J. A., & Cattran, D. C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00873.x · Cited by 257
Mycophenolate mofetil treatment for primary glomerular diseases
Choi, M. J., Eustace, J. A., Gimenez, L. F., Atta, M. G., Scheel, P. J., Sothinathan, R., & Briggs, W. A. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00214.x · Cited by 231
Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies
Rosenbloom, J., Castro, S. V., & Jimenez, S. A. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-3-201002020-00007 · Cited by 226
Mould, D. R., & Green, B. (2010) · BioDrugs · doi:10.2165/11530560-000000000-00000 · Cited by 207
Renoprotection: One or many therapies?
Hebert, L. A., Wilmer, W. A., Falkenhain, M. E., Ladson-Wofford, S. E., Nahman, N. S., & Rovin, B. H. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041211.x · Cited by 191
Kang, Y. S., Li, Y., Dai, C., Kiss, L. P., Wu, C., & Liu, Y. (2010) · Kidney International · doi:10.1038/ki.2010.137 · Cited by 150
Activation of the TGF- β/Smad signaling pathway in focal segmental glomerulosclerosis
Kim, J. H., Kim, B. K., Moon, K. C., Hong, H. K., & Lee, H. S. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00288.x · Cited by 148
Ruf, R. G., Schultheiß, M., Lichtenberger, A., Karle, S. M., Zalewski, I., Mucha, B. E., Everding, A. S., Neuhaus, T. J., Patzer, L., Plank, C., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00775.x · Cited by 144
Therapeutic Role of TGF-β–Neutralizing Antibody in Mouse Cyclosporin A Nephropathy
Ling, H., Li, X., Jha, S. S., Wang, W., Karetskaya, L., Pratt, B. M., & Ledbetter, S. R. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000042168.43665.9b · Cited by 126
Self-citationAdvances in the Biology and Genetics of the Podocytopathies: Implications for Diagnosis and Therapy
Barisoni, L. M. C., Schnaper, H. W., & Kopp, J. B. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.2.201 · Cited by 102
Morris, J. C., Shapiro, G. I., Tan, A. R., Lawrence, D. P., Olencki, T. E., Dezube, B. J., Hsu, F. J., Reiss, M., & Berzofsky, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.9028 · Cited by 78
Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity
Cho, M. E., Hurley, J. K., & Kopp, J. B. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.10.020 · Cited by 69
Transforming Growth Factor-β, 20-HETE Interaction, and Glomerular Injury in Dahl Salt-Sensitive Rats
Dahly-Vernon, A. J., Sharma, M., McCarthy, E. T., Savin, V. J., Ledbetter, S. R., & Roman, R. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000153791.89776.43 · Cited by 67
Self-citationvan Essen, G. G., Apperloo, A. J., Rensma, P. L., Stegeman, C. A., Sluiter, W. J., de Zeeuw, D., & de Jong, P. E. (1997) · PubMed · Cited by 49
PKC-alpha Modulates TGF-β Signaling and Impairs Podocyte Survival
Tossidou, I., Starker, G., Krueger, J., Meier, M., Leitges, M., Haller, H. G., & Schiffer, M. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000257518 · Cited by 46
Benigni, A., Zoja, C., Campana, M., et al. (2006) · Nephron Experimental Nephrology · doi:10.1159/000094967 · Cited by 46
ACE-inhibitors: panacea for progressive renal disease?
Navis, G., de Zeeuw, D., & de Jong, P. E. (1997) · The Lancet · doi:10.1016/s0140-6736(97)22026-x · Cited by 38
p35, the non-cyclin activator of Cdk5, protects podocytes against apoptosis in vitro and in vivo
Brinkkoetter, P. T., Wu, J. S., Ohse, T., Krofft, R. D., Schermer, B., Benzing, T. R., Pippin, J. W., & Shankland, S. J. (2010) · Kidney International · doi:10.1038/ki.2009.548 · Cited by 37
Therapeutic approach to FSGS in children
Gipson, D. S., Gibson, K. L., Gipson, P. E., Watkins, S. L., & Moxey‐Mims, M. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0310-4 · Cited by 36
Self-citationTherapeutic potential of TGF-β inhibition in chronic renal failure
Gagliardini, E., & Benigni, A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.293 · Cited by 35
Shiiki, H., & Dohi, K. (2000) · Internal Medicine · doi:10.2169/internalmedicine.39.606 · Cited by 21
McLaughlin, K. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.1.25 · Cited by 19
Cited by
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295
Transforming growth factor–β in tissue fibrosis
Frangogiannis, N. G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190103 · Cited by 1,278
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Metadata
- Authors
- Trachtman, H., Fervenza, F. C., Gipson, D. S., Heering, P., Jayne, D. R. W., Peters, H., Rota, S., Remuzzi, G., Rump, L. C., Sellin, L. K., Heaton, J. P. W., Streisand, J. B., Hard, M. L., Ledbetter, S. R., & Vincenti, F.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 79
- Issue
- 11
- Pages
- 1236-1243
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2112988722
- Cited by
- 263
- References
- 34
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.